304 related articles for article (PubMed ID: 19578355)
21. In prostatism patients the ratio of human glandular kallikrein to free PSA improves the discrimination between prostate cancer and benign hyperplasia within the diagnostic "gray zone" of total PSA 4 to 10 ng/mL.
Kwiatkowski MK; Recker F; Piironen T; Pettersson K; Otto T; Wernli M; Tscholl R
Urology; 1998 Sep; 52(3):360-5. PubMed ID: 9730444
[TBL] [Abstract][Full Text] [Related]
22. Discrimination of men with prostate cancer from those with benign disease by measurements of human glandular kallikrein 2 (HK2) in serum.
Becker C; Piironen T; Pettersson K; Björk T; Wojno KJ; Oesterling JE; Lilja H
J Urol; 2000 Jan; 163(1):311-6. PubMed ID: 10604382
[TBL] [Abstract][Full Text] [Related]
23. Improving the evaluation and diagnosis of clinically significant prostate cancer in 2017.
Carlsson SV; Roobol MJ
Curr Opin Urol; 2017 May; 27(3):198-204. PubMed ID: 28221219
[TBL] [Abstract][Full Text] [Related]
24. The role of biomarkers in the assessment of prostate cancer risk prior to prostate biopsy: which markers matter and how should they be used?
Schmid M; Trinh QD; Graefen M; Fisch M; Chun FK; Hansen J
World J Urol; 2014 Aug; 32(4):871-80. PubMed ID: 24825472
[TBL] [Abstract][Full Text] [Related]
25. Screening for prostate cancer in 2008 II: the importance of molecular subforms of prostate-specific antigen and tissue kallikreins.
Jansen FH; Roobol M; Jenster G; Schröder FH; Bangma CH
Eur Urol; 2009 Mar; 55(3):563-74. PubMed ID: 19058905
[TBL] [Abstract][Full Text] [Related]
26. Free PSA isoforms and intact and cleaved forms of urokinase plasminogen activator receptor in serum improve selection of patients for prostate cancer biopsy.
Steuber T; Vickers A; Haese A; Kattan MW; Eastham JA; Scardino PT; Huland H; Lilja H
Int J Cancer; 2007 Apr; 120(7):1499-504. PubMed ID: 17205511
[TBL] [Abstract][Full Text] [Related]
27. Serum human glandular kallikrein-2 protease levels predict the presence of prostate cancer among men with elevated prostate-specific antigen.
Nam RK; Diamandis EP; Toi A; Trachtenberg J; Magklara A; Scorilas A; Papnastasiou PA; Jewett MA; Narod SA
J Clin Oncol; 2000 Mar; 18(5):1036-42. PubMed ID: 10694554
[TBL] [Abstract][Full Text] [Related]
28. Patented prostate cancer biomarkers.
Murphy L; Watson RW
Nat Rev Urol; 2012 Aug; 9(8):464-72. PubMed ID: 22750955
[TBL] [Abstract][Full Text] [Related]
29. CCL11 (eotaxin-1): a new diagnostic serum marker for prostate cancer.
Agarwal M; He C; Siddiqui J; Wei JT; Macoska JA
Prostate; 2013 May; 73(6):573-81. PubMed ID: 23059958
[TBL] [Abstract][Full Text] [Related]
30. Value of Intact Prostate Specific Antigen and Human Kallikrein 2 in the 4 Kallikrein Predictive Model: An Individual Patient Data Meta-Analysis.
Vickers A; Vertosick EA; Sjoberg DD; Hamdy F; Neal D; Bjartell A; Hugosson J; Donovan JL; Villers A; Zappala S; Lilja H
J Urol; 2018 Jun; 199(6):1470-1474. PubMed ID: 29366640
[TBL] [Abstract][Full Text] [Related]
31. Beyond the biomarker role: prostate-specific antigen (PSA) in the prostate cancer microenvironment.
Moradi A; Srinivasan S; Clements J; Batra J
Cancer Metastasis Rev; 2019 Sep; 38(3):333-346. PubMed ID: 31659564
[TBL] [Abstract][Full Text] [Related]
32. Prostate-specific antigen and other serum and urine markers in prostate cancer.
Stephan C; Ralla B; Jung K
Biochim Biophys Acta; 2014 Aug; 1846(1):99-112. PubMed ID: 24727384
[TBL] [Abstract][Full Text] [Related]
33. The predictive value of prostate cancer biomarkers depends on age and time to diagnosis: towards a biologically-based screening strategy.
Vickers AJ; Ulmert D; Serio AM; Björk T; Scardino PT; Eastham JA; Berglund G; Lilja H
Int J Cancer; 2007 Nov; 121(10):2212-7. PubMed ID: 17657743
[TBL] [Abstract][Full Text] [Related]
34. Reducing unnecessary biopsy during prostate cancer screening using a four-kallikrein panel: an independent replication.
Vickers A; Cronin A; Roobol M; Savage C; Peltola M; Pettersson K; Scardino PT; Schröder F; Lilja H
J Clin Oncol; 2010 May; 28(15):2493-8. PubMed ID: 20421547
[TBL] [Abstract][Full Text] [Related]
35. Serum human glandular kallikrein (hK2) and insulin-like growth factor 1 (IGF-1) improve the discrimination between prostate cancer and benign prostatic hyperplasia in combination with total and %free PSA.
Scorilas A; Plebani M; Mazza S; Basso D; Soosaipillai AR; Katsaros N; Pagano F; Diamandis EP
Prostate; 2003 Feb; 54(3):220-9. PubMed ID: 12518327
[TBL] [Abstract][Full Text] [Related]
36. Human Kallikrein-2, Prostate Specific Antigen and Free- Prostate Specific Antigen in Combination to Discriminate Prostate Cancer from Benign Diseases in Syrian Patients.
Bachour DM; Chahin E; Al-Fahoum S
Asian Pac J Cancer Prev; 2015; 16(16):7085-8. PubMed ID: 26514494
[TBL] [Abstract][Full Text] [Related]
37. Time to replace prostate-specific antigen (PSA) with the Prostate Health Index (PHI)? Yet more evidence that the PHI consistently outperforms PSA across diverse populations.
Loeb S
BJU Int; 2015 Apr; 115(4):500. PubMed ID: 25808708
[No Abstract] [Full Text] [Related]
38. Development of monoclonal antibodies specific for human glandular kallikrein (hK2): development of a dual antibody immunoassay for hK2 with negligible prostate-specific antigen cross-reactivity.
Finlay JA; Evans CL; Day JR; Payne JK; Mikolajczyk SD; Millar LS; Kuus-Reichel K; Wolfert RL; Rittenhouse HG
Urology; 1998 May; 51(5):804-9. PubMed ID: 9610595
[TBL] [Abstract][Full Text] [Related]
39. [Biological markers of prostate cancer].
Seitz C; Djavan B
Ann Urol (Paris); 2006 Dec; 40(6):329-35. PubMed ID: 17214230
[TBL] [Abstract][Full Text] [Related]
40. Development of sensitive immunoassays for free and total human glandular kallikrein 2.
Väisänen V; Eriksson S; Ivaska KK; Lilja H; Nurmi M; Pettersson K
Clin Chem; 2004 Sep; 50(9):1607-17. PubMed ID: 15247158
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
